PTHS — Pelthos Therapeutics Inc.
AMEX · Healthcare · Biotechnology
$24.66
-$0.16 (-0.66%)
Pelthos Therapeutics Inc. (PTHS) is a biotechnology company listed on AMEX. It is led by Scott M. Plesha, based in 4020 Stirrup Creek Drive, Durham, NC, United States, 27703, with about 92 employees. Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Latest reported PTHS revenue for 2025-09-30 was $7.4M. Net income was -$16.2M. PTHS currently screens at market cap $94.7M.
Use this PTHS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PTHS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PTHS SEC filings page. Lician reads the product cache first so this HTML stays unique to Pelthos Therapeutics Inc. even when a live quote feed is slow.
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
PTHS Key Statistics
Market Cap
$94.75M
Volume
50,905
Previous Close
$26.62
Day Range
$25.97 – $28.17
P/B Ratio
2.67
EPS
-$1.43
Revenue
$0.00
Net Income
-$7.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
92
PTHS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.96M | -$7.38M | -$2.46M |
| EPS (Diluted) | -$1.43 | -$5.78 | $0.00 |
Total Assets
$1.37M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$513.44K
Operating Cash Flow
-$5.79M
Free Cash Flow
$0.00
Pelthos Therapeutics Inc. Company Information
- CEO, President & Director
- Scott M. Plesha
- Headquarters
- 4020 Stirrup Creek Drive, Durham, NC, United States, 27703
- Website
- pelthos.com
- Phone
- 919 908 2400
- IPO / Founded
- 2024-02-16
- Sector
- Healthcare
- Industry
- Biotechnology